A Role for Emerging Obesity Drugs

Current Cardiovascular Risk Reports

Volumn 6, Issue 3, 2012, Pages 185-187

  Rao, Goutham ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Bupropion; Drug therapy; Naltrexone; Obesity; Phentermine; Topiramate

Indexed keywords

AMFEBUTAMONE; ANTIOBESITY AGENT; EXENDIN 4; FENFLURAMINE; LIRAGLUTIDE; NALTREXONE; PHENTERMINE; PHENTERMINE PLUS TOPIRAMATE; PRAMLINTIDE; RIMONABANT; SIBUTRAMINE; TETRAHYDROLIPSTATIN;

BODY MASS; DRUG WITHDRAWAL; HUMAN; LIFESTYLE MODIFICATION; MENTAL DISEASE; OBESITY; PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION;

EID: 84873442578     PISSN: 19329520     EISSN: 19329563     Source Type: Journal    
DOI: 10.1007/s12170-012-0228-2     Document Type: Review

References (20)

1. Lake A, Townshend T. Obesogenic environments: exploring the built and food environments. J R Soc Promot Health. 2006; 126(6): 262-7.
2. Kersh R, Morone JA. Obesity, courts, and the new politics of public health. J Health Polit Pol Law. 2005; 30(5): 839-68.
3. Koplan JD, Brownell KD. Response of the food and beverage industry to the obesity threat. JAMA. 2010; 304(13): 1487-8.
4. Lemonick MD. Will we keep getting fatter? Time. com. http://www. time. com/time/magazine/article/0, 9171, 992522, 00. html. Accessed 25 January 2012.
5. FDA. Meridia (sibutramine): market withdrawal due to risk of serious cardiovascular events. http://www. fda. gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm228830. htm. Accessed 25 January 2012.
6. Sennik D. Withdrawal of the marketing authorisation for rimonabant in the European Union - EMEA statement. http://www. nelm. nhs. uk/en/NeLM-Area/News/2009-February/13/Withdrawal-of-the-marketing-authorisation-for-rimonabant-in-the-European-Union-EMEA-statement/. Accessed 25 January 2012.
7. Redux to be voluntarily withdrawn. Pondimin also to be withdrawn. http://www. antidepressantsfacts. com/redux-3. htm. Accessed 25 January 2012.
8. Kushner RF. Pharmacologic management of obesity. Pdiatr Blood Caner. 2012; 58: 140-3.
9. Rucker D, Padwal R, Li SK, Curioni C, Lau DC. Long term pharmacotherapy for obesity and overweight: updated meta-analysis [published correction appears in BMJ. 2007; 335(7629)]. BMJ. 2007; 335(7631): 1194-9.
10. Wing RR, Lang W, Wadden TA, Safford M, Knowler WC, Bertoni AG, Hill JO, Brancati FL, Peters A, Wagenknecht L. Look AHEAD Research Group. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care. 2011; 34(7): 1481-6.
11. Yao F, Mackenzie RG. Obesity drug update: the lost decade. Pharmaceuticals. 2010; 3: 3494-521.
12. Institute for Clinical Systems Improvement (ICSI). Prevention and management of obesity (mature adolescents and adults). Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2011.
13. Centers for Disease Control. http://www. cdc. gov/obesity/data/trends. html. Accessed 25 January 2012.
14. Nayak UA, Govindan J, Baskar V, Kalupahana D, Singh BM. Exenatide therapy in insulin-treated diabetes and obesity. QJM. 2010; 103(9): 687-94.
15. Dunican KC, Adamns NM, Desilets AR. The role of pramlintide for weight loss. Ann Pharmacother. 2010; 44(3): 538-45.
16. Astrup A, Rössner S, van Gaal L, Rissanen A, Niskanen L, Al Hakim M, Madsen J, Rasmussen MF, Lean ME. NN8022-1807 Study Group. Effects of liraglutide in the treatment of obesity: a randomized, double-blind, placebo-controlled study. Lancet. 2009; 374(9701): 1606-16.
17. Omellas T, Chavez B. Naltrexone SR/Bupropion SR (Contrave): A new approach to weight loss in obese adults. PT 2001; 36(5): 255-6, 261-2.
18. Drugs. com. http://www. drugs. com/nda/contrave_110920. html. Accessed 25 January 2012.
19. Allison DB, Gadde KM, Garvey WT, Peterson CA, Schwiers ML, Najarian T, et al. Controlled-Release Phentermine/Topiramate in Severely Obese Adults: A Randomized Controlled Trial (EQUIP). Obesity 2011; Nov 3. doi: 10. 1038/oby. 2011. 330. [Epub ahead of print].
20. Drugs. com. http://www. drugs. com/nda/qnexa_120109. html. Accessed 25 January 2012.